1. Epoetin alpha improves the response to antiviral treatment in HCV-related chronic hepatitis.
- Author
-
Bertino G, Ardiri A, Boemi PM, Calvagno GS, Ruggeri IM, Speranza A, Santonocito MM, Ierna D, Bruno CM, Valenti M, Boemi R, Naimo S, and Neri S
- Subjects
- Adult, Anemia, Hypochromic chemically induced, Drug Administration Schedule, Drug Therapy, Combination, Epoetin Alfa, Female, Ferritins blood, Hemoglobins metabolism, Hepacivirus drug effects, Hepacivirus genetics, Hepacivirus isolation & purification, Humans, Interferon alpha-2, Interferon-alpha administration & dosage, Interferon-alpha adverse effects, Longitudinal Studies, Male, Middle Aged, Polyethylene Glycols administration & dosage, Polyethylene Glycols adverse effects, Prospective Studies, Quality of Life, RNA, Viral analysis, Recombinant Proteins, Ribavirin administration & dosage, Ribavirin adverse effects, Treatment Outcome, Viral Load, Anemia, Hypochromic drug therapy, Antiviral Agents administration & dosage, Antiviral Agents adverse effects, Erythropoietin therapeutic use, Hematinics therapeutic use, Hepatitis C, Chronic drug therapy
- Abstract
Background: The conventional antiviral treatment of chronic hepatitis related to hepatitis C virus (HCV) often leads to anemia. In this case, it is necessary to reduce ribavirin dose or stop treatment, thus reducing the rate of sustained virological response., Aim: We investigated whether epoetin alpha administration improves treatment adherence and leads to higher percentage of response at the end of therapy and sustained virological response., Methods: Two hundred and fourteen individuals with genotype 1b HCV-related chronic hepatitis underwent treatment with pegylated (peg)-interferon alpha-2A 180 μg once weekly and ribavirin 1,000-1,200 mg/day; 174 were responders. Forty individuals completed treatment with no hemoglobin reduction; 134 developed anemia during therapy. Anemic responders were distributed randomly into two groups: group 1 continued therapy with epoetin alpha addiction; group 2 continued antiviral therapy with ribavirin reduction only., Results: Patients in group 1 achieved better control of hemoglobin levels (13.8 ± 1.2 g/dl at the end of therapy) than those in group 2 (11.5 ± 0.8 g/dl). Sustained virological response was 59.7% in group 1 compared with 34.4% in group 2 (p<0.01)., Conclusions: In patients with 1b HCV-related chronic hepatitis who develop anemia during antiviral treatment, administration of epoetin alpha increases hemoglobin levels and the end-of-treatment rate and sustains virological response by improving treatment adherence.
- Published
- 2010
- Full Text
- View/download PDF